Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Roche Holding AG agreed to buy Telavant Holdings for $7.1 billion. The Swiss healthcare firm that operates pharmaceuticals and diagnostics businesses worldwide announced on Monday, Oct. 23, that it will acquire the developer of a new treatment for inflammatory bowel diseases that Roivant Sciences and Pfizer Inc. own with a minority stake.
According to Reuters, Roche Holding will have the right to develop, produce, and commercially market Roivant Sciences and Pfizer's experimental antibody called the RVT-3101 under the terms. Roche is aiming to release this drug in the United States and Japan.
RVT-3101 in Phase 3 Trial
Roche reportedly said the RVT-3101 is a "promising" new therapy currently being developed to help patients suffering from inflammatory bowel disease, ulcerative colitis, and Crohn's disease. This bowel disease is part of a chronic gastrointestinal disorder group that affects about eight million people worldwide.
It was added that 80% of the patients are not experiencing lasting remission. Roche believes that the new RVT-3101 or TL1A antibody has a big potential to help treat other diseases. The pharma company said the drug is already close to phase 3 of the trial.
"Promising" New Treatment
"We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," Roche Group's chief executive officer, Thomas Schinecker, said in a press release. "We are excited to add this promising new therapy in development to our portfolio and to make it available to patients as quickly as possible."
Roche's chief medical officer, who also serves as the company's head of global product development, further said, "The recent Phase 2b for RVT-3101 delivered the first long-term, robust dataset demonstrating improved clinical remission in the maintenance treatment phase and with this promising data, we believe that RVT-3101 has the potential to be the first therapy that offers both high efficacy and safety for people with inflammatory bowel disease and the convenience of an at-home, subcutaneous administration."
Photo by: Roche Media Library
